Hisamitsu Pharmaceutical Co (FRA:HPX) Other Current Liabilities: €214.5 Mil (As of Nov. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:HPX Hisamitsu Pharmaceutical Co Inc FRA:HPX
65 GF Score
Price €31.80
GF Value €25.90
View Full Analysis

What is Hisamitsu Pharmaceutical Co Other Current Liabilities?

Hisamitsu Pharmaceutical Co FRA:HPX 65 Other Current Liabilities is €214.5 Mil as of Nov. 2025. GuruFocus rates FRA:HPX with a GF Score™ of 65/100 and a GF Value™ of €25.90.

Hisamitsu Pharmaceutical Co's other current liabilities for the quarter that ended in Nov. 2025 was €214.5 Mil.

Hisamitsu Pharmaceutical Co's quarterly other current liabilities increased from May. 2025 (€209.5 Mil) to Aug. 2025 (€212.6 Mil) and increased from Aug. 2025 (€212.6 Mil) to Nov. 2025 (€214.5 Mil).

Hisamitsu Pharmaceutical Co's annual other current liabilities declined from Feb. 2024 (€155.2 Mil) to Feb. 2025 (€152.4 Mil) and declined from Feb. 2025 (€152.4 Mil) to Feb. 2026 (€142.2 Mil).

Hisamitsu Pharmaceutical Co Other Current Liabilities Related Terms

Hisamitsu Pharmaceutical Co Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Hisamitsu Pharmaceutical Co's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hisamitsu Pharmaceutical Co Other Current Liabilities Chart

Hisamitsu Pharmaceutical Co Annual Data
Trend Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24 Feb25 Feb26
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 104.18 170.18 155.17 152.41 142.23

Hisamitsu Pharmaceutical Co Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 152.41 209.48 212.62 214.49 142.23
FRA:HPX
65GF Score
Hisamitsu Pharmaceutical Co Inc FRA:HPX
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hisamitsu Pharmaceutical Co Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of €214.5 Mil mean?
Hisamitsu Pharmaceutical Co (FRA:HPX) has a Other Current Liabilities of €214.5 Mil as of Nov. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Hisamitsu Pharmaceutical Co.
Is Hisamitsu Pharmaceutical Co's Other Current Liabilities too high?
Hisamitsu Pharmaceutical Co's current Other Current Liabilities is €214.5 Mil. Overall, Hisamitsu Pharmaceutical Co has a GF Score™ of 65/100, reflecting its overall financial health beyond just this single metric.
How does Hisamitsu Pharmaceutical Co's Other Current Liabilities compare to ESPR and AMPH?
Hisamitsu Pharmaceutical Co's Other Current Liabilities of €214.5 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Hisamitsu Pharmaceutical Co. Hisamitsu Pharmaceutical Co's current Other Current Liabilities is €214.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hisamitsu Pharmaceutical Co stock overvalued right now?
Hisamitsu Pharmaceutical Co (FRA:HPX) has a current Other Current Liabilities of €214.5 Mil. The stock's GF Value™ is €25.90, compared to a current price of €31.80 — trading 22.8% above its estimated fair value. The current Other Current Liabilities is €214.5 Mil. Hisamitsu Pharmaceutical Co's overall GF Score™ is 65/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Hisamitsu Pharmaceutical Co (FRA:HPX), the current Other Current Liabilities is €214.5 Mil as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hisamitsu Pharmaceutical Co (FRA:HPX) Overvalued in 2026?

Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be overvalued. The current stock price of €31.80 is trading 22.8% above its estimated GF Value™ of €25.90.

Key valuation signals for FRA:HPX:

  • Other Current Liabilities: €214.5 Mil
  • GF Value™: €25.90 vs. price of €31.80 (22.8% above fair value)
  • GF Score™: 65/100

No single metric tells the full story. See the FRA:HPX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hisamitsu Pharmaceutical Co Business Description

Other Exchanges HTSUY:USA
Address 408 Tashiro Daikancho, Saga Prefecture, Tosu, JPN, 841-0017
Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.
65GF Score

Get the complete analysis for FRA:HPX

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€31.80
Price
€25.90
GF Value